CVRxCVRX
CVRX
About: CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
Employees: 206
0
Funds holding %
of 7,323 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
52% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 23
29% more call options, than puts
Call options by funds: $736K | Put options by funds: $569K
21% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 14
1% more funds holding
Funds holding: 93 [Q4 2024] → 94 (+1) [Q1 2025]
2% more capital invested
Capital invested by funds: $192M [Q4 2024] → $195M (+$3.19M) [Q1 2025]
1.14% less ownership
Funds ownership: 62.47% [Q4 2024] → 61.33% (-1.14%) [Q1 2025]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 1 (-1) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$7
18%
downside
Avg. target
$9.50
11%
upside
High target
$12
41%
upside
2 analyst ratings
1 positive
50%
0 neutral
0%
1 negative
50%
Piper Sandler Matt O'Brien | 41%upside $12 | Overweight Maintained | 9 May 2025 |
JP Morgan Robbie Marcus | 18%downside $7 | Underweight Downgraded | 9 May 2025 |
Financial journalist opinion
Based on 5 articles about CVRX published over the past 30 days
Neutral
GlobeNewsWire
1 day ago
CVRx to Present at the Canaccord Genuity 45th Annual Growth Conference
MINNEAPOLIS, July 29, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025. The Company is scheduled to present at 3:00pm Eastern Time the same day via webcast.
Negative
Zacks Investment Research
2 days ago
CVRx (CVRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
CVRx (CVRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Positive
Zacks Investment Research
1 week ago
CVRx (CVRX) Surges 19.0%: Is This an Indication of Further Gains?
CVRx (CVRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Neutral
GlobeNewsWire
2 weeks ago
CVRx Announces Positive News on Outpatient Payment for Barostim
MINNEAPOLIS, July 16, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that the Centers for Medicare and Medicaid Services (CMS) has proposed to keep the Barostim implant procedure as part of the New Technology Ambulatory Payment Classification (APC) 1580, with an associated payment of approximately $45,000 for procedures performed in the outpatient setting. CMS is also soliciting comments about the need for a Level 6 Neurostimulator APC. We expect CMS will publish the 2026 Medicare Hospital Outpatient Prospective Payment System (OPPS) final rule in November, which is expected to take effect on January 1, 2026.
Neutral
Seeking Alpha
4 weeks ago
CVRx: Sell-Off Ignores Its True Potential
CVRx offers a unique, FDA-approved heart failure therapy with Medicare reimbursement, positioning it for significant market adoption and growth. The recent share price drop is an overreaction to sales force restructuring and reimbursement fears, while earnings and revenue estimates remain stable. Current valuation is deeply discounted versus sector peers, despite high-teens revenue growth and clear operating leverage potential as sales ramp up.
Neutral
GlobeNewsWire
2 months ago
CVRx to Present at the William Blair 45th Annual Growth Stock Conference
MINNEAPOLIS, May 28, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the William Blair 45th Annual Growth Stock Conference on Wednesday, June 4, 2025. The Company is scheduled to present at 10:00am Central Time the same day via webcast.
Neutral
Seeking Alpha
2 months ago
CVRx, Inc. (CVRX) Q1 2025 Earnings Conference Call Transcript
CVRx, Inc. (NASDAQ:CVRX ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Kevin Hykes - President & CEO Jared Oasheim - CFO Mike Vallie - IR, ICR Healthcare Conference Call Participants Macauley Kilbane - William Blair Nelson Cox - Lake Street Capital Markets Chase Knickerbocker - Craig-Hallum Capital Group Ross Osborn - Cantor Fitzgerald Operator Good day, everyone, and welcome to today's CVRx Q1 2025 earnings call. At this time, all participants are in a listen-only mode.
Negative
Zacks Investment Research
2 months ago
CVRx (CVRX) Reports Q1 Loss, Tops Revenue Estimates
CVRx (CVRX) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to loss of $1.04 per share a year ago.
Negative
Zacks Investment Research
2 months ago
CVRx (CVRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
CVRx (CVRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
GlobeNewsWire
3 months ago
CVRx to Report First Quarter 2025 Financial and Operating Results and Host Conference Call on May 8, 2025
MINNEAPOLIS, April 24, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that it plans to release first quarter 2025 financial and operating results after market close on Thursday, May 8, 2025. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day.
Charts implemented using Lightweight Charts™